A PHASE-II, OPEN-LABEL STUDY TO EVALUATE 2 DIFFERENT SCHEDULES FOR INTEGRATING FILGRASTIM (RECOMBINANT-METHIONYL HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR) AS ADJUVANT THERAPY IN THE TREATMENT OF PATIENTS WITH HODGKINS LYMPHOMA RECEIVING MOPP ABV HYBRID CHEMOTHERAPY/

Citation
G. Cantin et al., A PHASE-II, OPEN-LABEL STUDY TO EVALUATE 2 DIFFERENT SCHEDULES FOR INTEGRATING FILGRASTIM (RECOMBINANT-METHIONYL HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR) AS ADJUVANT THERAPY IN THE TREATMENT OF PATIENTS WITH HODGKINS LYMPHOMA RECEIVING MOPP ABV HYBRID CHEMOTHERAPY/, Blood, 86(10), 1995, pp. 197-197
Citations number
NO
Categorie Soggetti
Hematology
Journal title
BloodACNP
ISSN journal
00064971
Volume
86
Issue
10
Year of publication
1995
Supplement
1
Pages
197 - 197
Database
ISI
SICI code
0006-4971(1995)86:10<197:APOSTE>2.0.ZU;2-G